Ajinomoto Co. Inc. (TYO:2802) is positioning cutting-edge operations as a driver of future business growth for its contract manufacturing of…...
Please subscribe to read the full story.
antibody-drug conjugates
Daiichi Sankyo Sees Pillar of Growth in Next-Gen Biopharmaceuticals
Daiichi Sankyo Co. Ltd. (TYO:4568) is making antibody drug conjugates (ADCs) and other next-generation biopharmaceuticals a pillar for medium- and…...
Please subscribe to read the full story.
Nanocarrier Plans US Clinical Trials for Antibody-Drug Conjugated Micelles
Nanocarrier Co. Ltd. (TYO:4571) plans to apply in fiscal 2018 to conduct Phase I clinical trials in the U.S. using…...
Please subscribe to read the full story.
